Because depletion of EZH2 suppressed ER-negative tumor growth and metastasis in preclinical models (78), EZH2 has emerged as a potential therapeutic target for triple-negative breast cancer (TNBC). Here, EZH2 is linked to triple-negative breast carcinoma.